For example, Eli Lilly reports that its average rebates and discounts as a share of list price increased from 28% to 46% between 2012 and 2018, whereas Merck’s average rebates rose from 30% to 44% over this same period.[11] Between 2016 and 2018, Janssen reports that its average rebates and discounts rose from 35% to 47% of list price.[12] In fact, average net drug prices for these companies fell in 2017 and 2018 despite list prices continuing to increase, as shown in Figure 1. This information reflects net discounting across the portfolios of manufacturers, so it is difficult to extrapolate these results industry-wide.
Hey there, fellow citizens of the internet! Today, we’re diving into the murky waters of drug pricing deals that have recently come to light, specifically those cozy agreements between the Trump administration and big pharma giants like Pfizer and Eli Lilly. Spoiler alert: they’re not as transparent as a glass of water.
So, what’s the deal? Well, it turns out that these secret contracts included some rather interesting—and by interesting, I mean eyebrow-raising—provisions. According to the ever-reliable Washington Post, these deals didn’t just cover the usual boring stuff like pricing. No, no! They also dabbled in tariff protections (because who doesn’t love a good tax break?) and confidentiality clauses that would make even the most seasoned spies nod in approval.
First up, let’s talk about drug prices. You might think that a government deal with pharmaceutical companies would lead to lower prices for us, the little people. But no! These contracts reportedly incentivized raising drug prices in international markets. Yes, you heard that right! While we’re all trying to figure out how to afford our prescriptions, these companies were given a nudge to hike prices elsewhere. It’s like a twisted version of “let’s make a deal,” where everyone wins—except for the public, of course.
Now, about those tariff protections. The contracts included clauses that shielded these companies from U.S. tariffs. Because what’s better than getting a government handout while simultaneously avoiding taxes? It’s a win-win for Pfizer and Eli Lilly, but for the average American? Not so much. It’s almost as if they’re saying, “Why should we pay our fair share when we can just make a secret deal?” Talk about a masterclass in corporate strategy!
And let’s not forget the confidentiality clauses. These are the kind of clauses that make you feel like you’re reading a script from a spy movie. You know, the kind where everything is shrouded in mystery, and the bad guys are always one step ahead. Only in this case, the bad guys are big pharmaceutical companies, and the stakes are our health and wallets.
So, why should you care? Well, unless you live under a rock (and if you do, I hope it’s a nice one), you’ve probably noticed that drug prices in the U.S. are through the roof. And while these companies are raking in profits, the rest of us are left trying to figure out how to pay for the medications we need. It’s a bit like being invited to a party where the snacks are all locked behind a glass case, and the key is held by someone who has no interest in sharing.
In conclusion, the revelations about these secret contracts are a stark reminder of how the pharmaceutical industry often operates behind closed doors. While we’re out here trying to navigate the complexities of healthcare, these companies are busy making deals that benefit them at our expense. So the next time you hear about rising drug prices, just remember: there’s likely a secret contract somewhere that explains why your wallet is feeling a little lighter.
Until next time, keep questioning and stay informed. After all, knowledge is power—and in this case, it might just help you afford your next prescription!
Inspired by: “Secret contracts reveal undisclosed terms in Trump’s drug-pricing deals” (r/Politics)